Table 1 Demographics and clinical measures^a.

	HC (n = 21)	FEP (n = 22)	t/X²	p value
Gender (% male)	62	64	0.01	0.91
Age	22.95 (5.01)	22.73 (5.52)	0.14	0.89
Parental occupation^b	3.95 (3.15)	4.95 (5.00)	−0.78	0.44
Smoking status (% smoker)	0	32	7.98	<0.01
Diagnosis
Schizophrenia		15
Schizoaffective disorder		5
Unspecified psychosis		2
Duration of untreated psychosis^c (mean; median; [range] in weeks)		124.55; 45; [1–626]
Risperidone dose week 6 (mean; median; [range] in mg)		3.61; 4; [1–8]
Risperidone dose at week 16 (mean, SD; median; [range] in mg)		4.65; 4; [0–8]
BPRS^d
Baseline
Total		50.91 (9.41)
Positive		11.55 (3.42)
Negative		7.41 (3.57)
Week 6
Total		34.00 (10.88)
Positive		5.67 (2.61)
Negative		6.17 (2.83)
Week 16
Total		34.44 (11.44)
Positive		5.44 (2.9)
Negative		6.94 (2.82)
RBANS^e
Total index	91.14 (13.32)	70.42 (14.61)	4.69	<0.01
Immediate memory	100.67 (15.57)	78.95 (16.7)	4.26	<0.01
Visuospatial	85.62 (13.67)	74.58 (15.21)	2.42	0.02
Language	94.81 (17.06)	81.79 (12.49)	2.73	<0.01
Attention span	94.62 (19.05)	75.16 (18.97)	3.23	<0.01
Delayed memory	91.81 (8.37)	71.53 (20.14)	4.23	<0.01

FEP first-episode psychosis, HC healthy control.
^aMean (SD) unless indicated otherwise.
^bRanks determined from Diagnostic Interview for Genetic Studies (1–18 scale); higher rank (lower numerical value) corresponds to higher socioeconomic status.
^cData on duration of untreated psychosis were not available for two patients.
^dBrief Psychiatric Rating Scale (1–7 scale); positive (conceptual disorganization, hallucinatory behavior, and unusual thought content); negative (emotional withdrawal, motor retardation, and blunted affect).
^dRepeatable Battery for the Assessment of Neuropsychological Status, data not available for three FEP.

Quick links

Search